The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Jul 2011 13:01

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Scancell Holdings plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Calculus Capital Limitednotification obligation:iii 4. Full name of shareholder(s) HSBC Global Custody (UK) Limited (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 26 July 2011reached: v 6. Date on which issuer notified: 26 July 2011 7. Threshold(s) that is/are crossed or 10,11,12,13%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction Number Number Number Number of voting % of voting rightsif possible of of of shares rights x using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii Ordinary Shares ISIN: 15,277,780 15,277,780 25,277,780 25,277,780 13.02 % GB00B39J5N63 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting % of voting financial date xvii Conversion rights instrument rights xix, xx instrument period refers to xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 25,277,780 13.02 %

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease N/Ato hold: 12. Date on which proxy holder will cease to hold N/Avoting rights: 13. Additional information: N/A 14. Contact name: Calculus Capital Limited 15. Contact telephone number: 0207 493 4940

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
8th Feb 20237:00 amRNSIssue of Equity
1st Feb 20237:00 amRNSDr Jean-Michel Cosséry appointed as Chairman
25th Jan 20237:00 amRNSInterim Results
18th Jan 20237:00 amRNSNotice of Interim Results
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20223:18 pmRNSResult of Annual General Meeting
7th Nov 20227:00 amRNSLicenses Vaccitech technology to advance Modi-2
31st Oct 20227:00 amRNSFirst patient dosed in expansion phase of ModiFY
28th Oct 20223:00 pmRNSNotice of AGM
28th Oct 20227:00 amRNSResults for the year ended 30 April 2022
26th Oct 20227:00 amRNSDirectorate Changes
25th Oct 20224:42 pmRNSSecond Price Monitoring Extn
25th Oct 20224:37 pmRNSPrice Monitoring Extension
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 202211:05 amRNSSecond Price Monitoring Extn
25th Oct 202211:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSSigns Commercial License Agreement with Genmab
13th Oct 20227:00 amRNSChange of Nominated Adviser
28th Sep 202212:31 pmRNSHolding(s) in Company
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
6th Sep 202212:54 pmRNSChange of Registered Office
16th Aug 20222:00 pmRNSFirst patient dosed in Cohort 2 of the ModiFY
23rd Jun 20227:00 amRNSScancell to produce TCB antibodies
15th Jun 20222:06 pmRNSSecond Price Monitoring Extn
15th Jun 20222:00 pmRNSPrice Monitoring Extension
15th Jun 20227:00 amRNSPhase 2 SCOPE trial of SCIB1 vaccine expanded
13th Jun 20227:00 amRNSFirst patient dosed in Modi-1 Phase 1 trial
12th Apr 20223:47 pmRNSChange of Registered Holder of Shares
11th Apr 20222:06 pmRNSSecond Price Monitoring Extn
11th Apr 20222:00 pmRNSPrice Monitoring Extension
11th Apr 202211:05 amRNSSecond Price Monitoring Extn
11th Apr 202211:00 amRNSPrice Monitoring Extension
11th Apr 20227:00 amRNSModi-1 Phase 1/2 trial open for recruitment
29th Mar 20227:00 amRNSUpdate on COVIDITY clinical trial
17th Mar 20227:00 amRNSScancell progresses its new anti-glycan mAb
3rd Mar 20229:55 amRNSDirector Dealing
31st Jan 20227:00 amRNSUpdate on COVIDITY Phase 1 clinical trial
26th Jan 20227:00 amRNSInterim Results for the 6 months ended 31 Oct 2021
22nd Dec 20219:45 amRNSNotice of Interim Results
13th Dec 20214:41 pmRNSSecond Price Monitoring Extn
13th Dec 20214:36 pmRNSPrice Monitoring Extension
23rd Nov 20213:58 pmRNSResult of AGM
19th Nov 20217:00 amRNSFirst patient dosed in SCIB1 Phase 2 trial
3rd Nov 202110:28 amRNSDirector Dealing
2nd Nov 202110:07 amRNSDirector Dealing
1st Nov 20219:50 amRNSNotice of Annual General Meeting
29th Oct 20217:00 amRNSResults for the year ended 30 April 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.